1-13 of 13
Eunice S. Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia

Clinical Trials & Observations
Mark Levis, Alexander Perl, Gary Schiller, Amir T. Fathi, Gail Roboz, Eunice S. Wang, Jessica Altman, Trivikram Rajkhowa, Makoto Ando, Takeaki Suzuki, Ruth Ann Subach, Gary Maier, Timothy Madden, Mary Johansen, Kin Cheung, Michael Kurman, Catherine Smith
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2527–2535.
https://doi.org/10.1182/bloodadvances.2023010619
Published: 2024
Includes: Supplemental data
Journal Articles

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results

Clinical Trials & Observations
Abdulraheem Yacoub, Uma Borate, Raajit K. Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O’Connell, Swati Goel, Stephen T. Oh, Gary Schiller, James McCloskey, Jeanne Palmer, Houston Holmes, Steven Hager, Albert Assad, Susan Erickson-Viitanen, Feng Zhou, Naval Daver
Journal: Blood Advances
Blood Adv (2024) 8 (6): 1515–1528.
https://doi.org/10.1182/bloodadvances.2023011620
Published: 2024
Includes: Supplemental data
Journal Articles

Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes

Harrison K. Tsai, Christopher J. Gibson, H. Moses Murdock, Phani Davineni, Marian H. Harris, Eunice S. Wang, Lukasz P. Gondek, Annette S. Kim, Valentina Nardi, R. Coleman Lindsley
Journal: Blood Advances
Blood Adv (2022) 6 (14): 4236–4240.
https://doi.org/10.1182/bloodadvances.2022007613
Published: 2022
Includes: Supplemental data
Journal Articles

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy

Jurjen Versluis, Manu Pandey, Yael Flamand, J. Erika Haydu, Roger Belizaire, Mark Faber, Rahul S. Vedula, Anne Charles, Kevin M. Copson, Shai Shimony, Alon Rozental, Pavan K. Bendapudi, Ofir Wolach, Elizabeth A. Griffiths, James E. Thompson, Richard M. Stone, Daniel J. DeAngelo, Donna Neuberg, Marlise R. Luskin, Eunice S. Wang, R. Coleman Lindsley
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2835–2846.
https://doi.org/10.1182/bloodadvances.2021006166
Published: 2022
Includes: Supplemental data
Journal Articles

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia

Clinical Trials & Observations
Sydney Fobare, Jessica Kohlschmidt, Hatice Gulcin Ozer, Krzysztof Mrózek, Deedra Nicolet, Alice S. Mims, Ramiro Garzon, James S. Blachly, Shelley Orwick, Andrew J. Carroll, Richard M. Stone, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, Christopher C. Oakes, Ann-Kathrin Eisfeld, Erin Hertlein, John C. Byrd
Journal: Blood Advances
Blood Adv (2022) 6 (5): 1371–1380.
https://doi.org/10.1182/bloodadvances.2021006242
Published: 2022
Includes: Supplemental data
Journal Articles

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Clinical Trials & Observations
Alison R. Walker, Guido Marcucci, Jun Yin, William Blum, Wendy Stock, Jessica Kohlschmidt, Krzysztof Mrózek, Andrew J. Carroll, Ann-Kathrin Eisfeld, Eunice S. Wang, Sawyer Jacobson, Jonathan E. Kolitz, Mohan Thakuri, Grerk Sutamtewagul, Ravi Vij, Robert K. Stuart, John C. Byrd, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2021) 5 (13): 2775–2787.
https://doi.org/10.1182/bloodadvances.2021004233
Published: 2021
Includes: Supplemental data
Journal Articles

Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis

Kaitlyn M. Dykstra, Hannah R. S. Fay, Ashish C. Massey, Neng Yang, Matthew Johnson, Scott Portwood, Monica L. Guzman, Eunice S. Wang
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2087–2100.
https://doi.org/10.1182/bloodadvances.2020002666
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase

Clinical Trials & Observations
John O. Mascarenhas, Raajit K. Rampal, Heidi E. Kosiorek, Rupali Bhave, Elizabeth Hexner, Eunice S. Wang, Aaron Gerds, Camille N. Abboud, Marina Kremyanskaya, Dimitry Berenzon, Olatoyosi Odenike, Noushin Farnoud, Aishwarya Krishnan, Rona Singer Weinberg, Erin McGovern, Mohamed E. Salama, Vesna Najfeld, Juan S. Medina-Martinez, Juan E. Arango Ossa, Max F. Levine, Yangyu Zhou, Lonette Sandy, Mark L. Heaney, Ross L. Levine, Ruben A. Mesa, Amylou C. Dueck, Ronald Hoffman
Journal: Blood Advances
Blood Adv (2020) 4 (20): 5246–5256.
https://doi.org/10.1182/bloodadvances.2020002119
Published: 2020
Includes: Supplemental data
Journal Articles

A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia

Clinical Trials & Observations
Catherine C. Smith, Mark J. Levis, Olga Frankfurt, John M. Pagel, Gail J. Roboz, Richard M. Stone, Eunice S. Wang, Paul L. Severson, Brian L. West, Mai H. Le, Sabine Kayser, Bao Lam, Henry H. Hsu, Chao Zhang, Gideon Bollag, Alexander E. Perl
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1711–1721.
https://doi.org/10.1182/bloodadvances.2020001449
Published: 2020
Includes: Supplemental data
Journal Articles

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Clinical Trials & Observations
Guido Marcucci, Susan Geyer, Kristina Laumann, Weiqiang Zhao, Donna Bucci, Geoffrey L. Uy, William Blum, Ann-Kathrin Eisfeld, Timothy S. Pardee, Eunice S. Wang, Wendy Stock, Jonathan E. Kolitz, Jessica Kohlschmidt, Krzysztof Mrózek, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2020) 4 (4): 696–705.
https://doi.org/10.1182/bloodadvances.2019000492
Published: 2020
Journal Articles

Clinical and functional significance of circular RNAs in cytogenetically normal AML

Clinical Trials & Observations
Dimitrios Papaioannou, Stefano Volinia, Deedra Nicolet, Michał Świerniak, Andreas Petri, Krzysztof Mrózek, Marius Bill, Felice Pepe, Christopher J. Walker, Allison E. Walker, Andrew J. Carroll, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Eunice S. Wang, Sakari Kauppinen, Adrienne Dorrance, Richard M. Stone, John C. Byrd, Clara D. Bloomfield, Ramiro Garzon
Journal: Blood Advances
Blood Adv (2020) 4 (2): 239–251.
https://doi.org/10.1182/bloodadvances.2019000568
Published: 2020
Includes: Supplemental data
Journal Articles

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia

Clinical Trials & Observations
Harry P. Erba, Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher, Min Zhu, Erik Rasmussen, Haby A. Henary, Abraham A. Anderson, Eunice S. Wang
Journal: Blood Advances
Blood Adv (2019) 3 (13): 1939–1949.
https://doi.org/10.1182/bloodadvances.2019030916
Published: 2019
Journal Articles

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Clinical Trials & Observations
Gail J. Roboz, Sumithra J. Mandrekar, Pinkal Desai, Kristina Laumann, Alison R. Walker, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, Eyal C. Attar, Wendy Stock, Clara D. Bloomfield, Jessica Kohlschmidt, Krzysztof Mrózek, Duane C. Hassane, Levi Garraway, Judit Jané-Valbuena, Michele Baltay, Adam Tracy, Guido Marcucci, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3608–3617.
https://doi.org/10.1182/bloodadvances.2018023689
Published: 2018
Includes: Supplemental data